Zinger Key Points
- Q1 revenue rose 20.3% YoY to $158.7M, beating estimates; adjusted EPS loss narrowed to $0.95 vs. $1.23 last year.
- Gross margin improved to 68.8% from 66.3% YoY, driven by volume leverage and operational efficiencies in Zio services.
- Today's manic market swings are creating the perfect setup for Matt’s next volatility trade. Get his next trade alert for free, right here.
iRhythm Technologies Inc IRTC on Thursday reported first quarter 2025 revenue of $158.7 million, up 20.3% year over year, beating the consensus of $153.38 million.
The increase was driven by growth in demand for Zio services.
The company reported an adjusted EPS loss of 95 cents, down from a loss of $1.23 a year ago, beating the consensus estimate of 98 cents.
Gross profit was $109.2 million, up 24.8% from $87.5 million during the same period in 2024, while gross margin was 68.8%, up from 66.3% during the same period in 2024.
- The increase in gross profit was primarily due to the increased volume of Zio services provided due to higher demand.
- The increase in gross margin was primarily due to volume leverage and operational efficiencies, partially offset by an increased blended cost per unit from a higher Zio AT product mix.
Quentin Blackford, CEO of iRhythm, noted the company’s recent commercial launch in Japan for a total of six markets outside the U.S.
On Thursday, iRhythm announced the commercial launch of its Zio long-term continuous ECG monitoring (LTCM) system, commercially introduced in Japan as the Zio ECG Recording and Analysis System.
Guidance: iRhythm projects fiscal 2025 sales guidance of $690 million-$700 million, compared to prior guidance of $675 million-$685 million and consensus of $681.56 million.
William Blair writes, “We view updates this quarter as further validation of our thesis playing out this year as Zio AT accelerates, management executes on its land and expand strategy, and the company is seeing early positive signals in adjacent opportunities.”
- Analyst Margaret Kaczor Andrew maintains the Outperform rating.
- Wells Fargo upgrades iRhythm Technologies from Equal-Weight to Overweight, raising the price target from $104 to $130.
- Baird maintains iRhythm with an Outperform rating, raising the price target from $133 to $150.
- Needham maintains iRhythm with a Buy, raising the price target from $138 to $151.
Price Action: IRTC stock is up 19.1% at $129.37 at the last check Friday.
Read Next:
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.